Coluracetam

Coluracetam (CAS No.: 135463-81-9) is a compound belonging to the racetam class, originally developed by Mitsubishi Tanabe Pharma and primarily studied in Alzheimer’s disease research. Its main mechanism of action is to promote acetylcholine synthesis by enhancing high-affinity choline uptake (HACU), thereby improving cognitive function. Studies show that in in vitro experiments, Coluracetam can significantly increase choline uptake capacity, with activity in the nanomolar to micromolar range. In animal models, oral administration of Coluracetam improved learning and memory impairments induced by ethylcholine mustard aziridinium (AF64A), indicating potential application value. The doses or concentrations used in experiments typically depend on the experimental design and research objectives.